Background and Aims: Crohn's disease [CD] is associated with an increased risk of small bowel adenocarcinoma [SBA]. There are no recommendations on endoscopic screening of SBA in CD patients. The aim of this study was to evaluate the feasibility and value of endoscopic screening for SBA in CD patients at high-risk of SBA. Methods: We performed an exploratory multi-centre study in a prospective cohort of CD patients at high-risk of SBA defined as long-term small bowel disease without bowel resection for the past 10 years. Depending on the location of the disease, baseline upper and/or lower enteroscopies were performed. Random and targeted biopsies using chromoendoscopy were taken. Patients were followed-up for at least 1 year after inclusion. Results: In total, 101 patients [62 men; median age: 48 years; median duration of disease: 19 years] were recruited in ten centres. The endoscopic procedure was incomplete in 47 cases because of impassable strictures and dilation was performed in four patients. Indeterminate small bowel dysplasia was identified in two patients at endoscopic screening; SBA was confirmed in one after surgical resection. With an at least 1-year follow-up duration, two additional cases of SBA were identified in patients who underwent surgery for obstruction, resulting in a 33% sensitivity rate for SBA endoscopic screening.
Introduction
Chronic inflammation from inflammatory bowel disease [IBD] favours colorectal carcinogenesis. 1 This has clearly been shown by the association between colorectal adenocarcinoma, ulcerative colitis and colonic Crohn's disease [CD] . Small bowel CD is also associated with an increased risk of small bowel adenocarcinoma [SBA] , with a standardized incidence ratio [SIR] of between 18.7 and 33.2 in four population-based meta-analyses. [2] [3] [4] [5] Indeed, patients who have had small bowel CD for more than 8 years have an incidence of SBA of 0.5 per 1000 patient-years, similar to the risk of sporadic colorectal cancer in the general population. 6 SBA complicating CD has a poor prognosis, with an estimated 5-year overall survival of 35%, 7 possibly due to a delayed diagnosis because most cases are not diagnosed before surgical resection is needed for complications such as obstruction or perforation. 8 There are very few existing data on the risk factors of SBA complicating CD, although isolated small bowel CD and long-term disease have been identified. 6, 9 Several series also suggest that complications such as strictures and fistulas and conservative surgical procedures [strictureplasties, excluded loops] may be associated with an increased risk of SBA. [10] [11] [12] [13] Conversely, in one case-control study, small bowel resection and long-term treatment with salicylates may have a protective effect. 9 Dysplasia is a reliable marker of an increased risk of colorectal cancer in patients with ulcerative colitis and CD colitis. Thus, endoscopic surveillance is recommended to detect dysplasia or early stage cancer in patients with long-term colonic IBD.
14 Even if the data are limited in small bowel CD, a chronic inflammation-dysplasiaadenocarcinoma sequence is also suspected in the pathogenesis of SBA. 15, 16 In one recent study of 45 surgical specimens of SBA complicating CD, cancer developed on a chronically inflamed area in 95% of patients and associated dysplasia was identified in half of them. 17 However, there are no data on endoscopic surveillance for dysplasia in CD patients at a high risk of SBA. The aim of the present study was to determine the feasibility and benefits of endoscopic screening for dysplasia and SBA in CD.
Methods

Study design and patients
A multi-centre, exploratory, prospective, cohort study was performed between February, 2010 and December, 2013 in nine French centres and one Dutch centre affiliated with the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID] . Inclusion criteria were [1] patients ≥ 18 years old, [2] with a diagnosis of CD based on usual criteria, 18 [3] at high risk of SBA defined by the location of small bowel disease -ileal, jejunal or both -with more than 10 years without intestinal resection and [4] with SB lesions that could be reached by upper and/or lower endoscopy according to investigator judgment. Cross-sectional imaging [magnetic resonance imaging or computed tomography] was performed within the year before inclusion. Patients with suspected SBA on cross-sectional imaging or with a contraindication to general anaesthesia were excluded. All patients provided written informed consent. The date of inclusion corresponded to the day of endoscopic screening.
Endoscopic screening procedure
The type of endoscopic screening -upper, lower or both -was based on the location of disease according to the history of CD and prior imaging. Standard colonoscopes, gastroscopes and enteroscopes [double, single balloon or spiral] could be used. The small bowel was explored as far as possible beyond the ileo-colic and/or duodenojejunal junction to examine the entire affected small bowel mucosa, which was divided into segments of 20 cm. Each 20-cm segment of small bowel mucosa was described as follows: active lesions [ulceration, oedema, erythema, stenosis and/or inflammatory polyps], healed lesions or normal mucosa. Chromoendoscopy with carmine indigo using a spray catheter was performed in all small bowel segments. Three random biopsies were obtained from each 20-cm segment of small bowel and additional targeted biopsies were obtained from mucosal abnormalities [flat, polypoid, depressed lesions and stenosis]. Stricture dilation was performed in patients with obstructive symptoms if needed and if it was considered feasible by the endoscopist. The procedure was considered to be complete when the entire mucosa of the affected small bowel could be visualized.
Biopsy samples were read by local pathologists in each centre. Inflammatory activity was classified into four categories: no inflammation, mild to moderate inflammation, severe inflammation and neoplastic changes [dysplasia and/or SBA]. Dysplasia was classified according to the new Vienna classification. 19 In case of dysplasia, biopsies were reviewed by a second IBD expert pathologist. Dysplasia was classified by both pathologists as indeterminate dysplasia, low-or high-grade dysplasia, or adenocarcinoma.
Follow-up
Patients were followed-up until 1 year after inclusion. The following events were recorded during the follow-up period: death, intestinal resection with histological analysis of the surgical specimen, small bowel dysplasia and SBA. The following data were recorded concerning endoscopic screening: approach, type of endoscope used, duration of the procedure, quality of bowel preparation, maximum length of small bowel mucosa explored [in cm] and the reason for any incomplete procedures, mucosal lesions in each 20-cm segment, location, number and indication [random and/or targeted] for the biopsies performed, and associated endoscopic dilation.
Data collection
Primary and secondary objectives
The primary end-point was the proportion of patients with bowel dysplasia and SBA detected on endoscopic screening.
Secondary end-points were: [1] feasibility of small bowel endoscopic screening defined by the proportion of patients with a complete procedure; [2] proportion of patients with visualization of at least one diseased segment during a procedure; [3] safety of small bowel endoscopic screening within the 60 days after inclusion; and [4] proportion of patients with SBA or dysplasia diagnosed at the end of the follow-up period.
Statistical analysis
Statistical analysis was performed on an intent-to-treat basis that is based on all included patients unless consent was withdrawn. 
Results
In total, 106 patients were screened in ten centres during the study period. Five patients were excluded from the study: three due to missing written informed consent, one for an unexpected contraindication to general anaesthesia [heart stroke] between screening and inclusion, and one for withdrawal of written informed consent. The patient flowchart is presented in Figure 1 .
Patient characteristics
The baseline characteristics of the 101 included patients are presented in Table 1 . Sixty-two patients were men, with a median age of 48 years [IQR: 39-58] and median disease duration of 19.0 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] years. The median duration of small bowel CD was 16 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] years, the ileum was involved in almost all cases [n = 99] and the jejunum in 17 patients. There was associated colonic CD in 45 patients. Fifty patients had undergone previous intestinal surgery, including small bowel resection in 47 cases and strictureplasty in nine. The median time until postoperative recurrence in patients who had undergone previous small bowel resection was 12 [IQR: [9] [10] [11] [12] [13] [14] 
Cross-sectional imaging had been performed within the year before inclusion in 83 patients and showed small bowel abnormalities related to CD [thickened bowel wall and/or a peri-digestive fat infiltration] in 79 patients, located in the proximal jejunum in five and the distal ileum in 74 cases. Single or multiple small bowel strictures were observed in 43 patients, associated with dilation above in 22 of them. Enteric fistulas were identified in nine patients on imaging.
Endoscopic screening
Detailed results of the 109 endoscopic procedures are provided in Table 2 . Lower exploration was performed in 95 patients and upper exploration in 14. Eight patients underwent both explorations. The median length of small bowel mucosa explored was 20 No case of SBA, or high-grade or low-grade dysplasia was identified. Indeterminate dysplasia was detected in two patients and confirmed by the reading of the second pathologist. The proportion of patients with small bowel dysplasia or SBA detected by endoscopic screening was 2% in our cohort. The first case was a patient who had had ileal CD for 27 years with no previous bowel resection and with recent obstructive symptoms. The endoscopic screening procedure only explored a few centimetres of the 90 cm of affected mucosa identified on imaging because of an impassable stricture. Biopsies identifying indeterminate dysplasia were obtained from the distal portion of the stricture. Undifferentiated SBA [T3N0M0] was diagnosed in the surgical resection specimen associated with both low-and high-grade adjacent dysplasia. The second patient had had ileal CD for 25 years, and was symptom free with azathioprine. A complete endoscopic screening procedure showed healed mucosa and identified indeterminate dysplasia in 3/10 random biopsies obtained from different segments. The patient refused surgery, and is still in remission after a follow-up of 4 years since inclusion.
Follow-up
The follow-up period was at least 1 year -five patients were lost to follow-up during this period -and its median duration was 1004 [30-2147] days. Eleven of the 99 patients without SBA or dysplasia after endoscopic screening developed severe obstructive symptoms during the 1-year follow-up and six underwent intestinal resection. Two additional cases of SBA were diagnosed. Both patients had long-term stricturing small bowel CD -13 and 19 years, respectively -with recent obstructive symptoms and a small bowel dilation without visible tumour on cross-sectional imaging performed within the month before inclusion. The endoscopic procedure was incomplete in both these patients due to an impassable stricture and the biopsies only identified chronic inflammation. Both low-and high-grade dysplasia were associated with SBA on these surgical specimens.
The global prevalence of dysplasia and/or SBA for the entire cohort was 4% at the end of the 1-year follow-up. One of the three cases of SBA was detected by endoscopic screening; the sensitivity of endoscopic screening for SBA was only 33%.
Discussion
The risk of SBA is 20-30 times higher in patients with small bowel CD than in the general population 2-5 with a poor prognosis. 7 Despite the potential benefit of early detection of dysplasia in the case of colorectal cancer on IBD, there are no existing data on endoscopic small bowel screening in CD. This is the first prospective study to evaluate the value of endoscopic screening in the detection of dysplasia and/or SBA in a cohort of high-risk CD patients. After 1 year of follow-up, the prevalence of SBA was 3%. However, the sensitivity of endoscopic screening for SBA was only 33%. 16 [16] CD, Crohn's disease; TNF, tumour necrosis factor; CRP, C-reactive protein; n, number of patients; CDAI, Crohn's disease activity index; IBD, inflammatory bowel disease; 5 ASA, 5 amino-salicylate.
The present study confirms an increased prevalence of SBA in CD patients with long-term small bowel disease. In previous studies this risk was identified at least 8 years after the diagnosis of CD while in our study the median duration of SB disease was longer, 16 years. 6, 9 Stricturing may also be a risk factor for SBA. Indeed, the cases of SBA observed in the present study were associated with impassable strictures. However, bowel damage is considered to be the natural history of small bowel CD leading to complications such as stricture or fistulas over time. 21 Even if it is unclear whether strictures per se are an independent risk factor of SBA or a confounding factor, they result in a high number of incomplete endoscopic screenings that can explain in part the poor sensitivity of this procedure. Thus, the low rate of dysplasia and SBA detected by endoscopy in our cohort was not due to inappropriate patient selection.
The pathogenesis of SBA complicating CD is poorly understood. It has been suggested that it could be inflammatory-driven like colorectal cancer on IBD because, as described in a recent retrospective French study, adenocarcinoma occurs in affected lesions and is associated with dysplasia. 17 This observation was confirmed in our cohort, because low-and high-grade dysplasias were identified close to the cancer on all the surgical specimens of patients with SBA.
The strength of the present study is its prospective design in a well-defined study population at high risk of SBA. Moreover, all endoscopic procedures were performed in tertiary centres with trained operators using chromoendoscopy for the detection of colorectal cancer on IBD in their daily practice. The diagnosis of dysplasia and SBA was confirmed by a second reading by an expert pathologist. None of the patients was lost to follow-up during the year after inclusion.
However, the present study has certain limitations. First, management of impassable strictures was not standardized. Thus, few patients with impassable strictures underwent endoscopic dilation and it is possible that dilation of all strictures would have increased the rate of detection of dysplasia or SBA. However, this approach is inappropriate for extended strictures and is associated with a risk of perforation. Second, although indeterminate small bowel dysplasia was detected at screening in one patient of our cohort, this patient did not undergo bowel resection during follow-up. It is unlikely that this indeterminate dysplasia was associated with SBA at inclusion because this patient was asymptomatic 4 years after inclusion. Interestingly, one case of small bowel dysplasia was reported in random biopsies that evolved to adenocarcinoma 18 months later. 22 It is important to note that all three cases of SBA in the present cohort were diagnosed in patients with recent, acute obstructive symptoms; cross-sectional imaging failed to detect small bowel tumour as usually observed in the literature. 6, 7 This suggests that surgery rather than medical treatment might first be considered in patients with long-term small bowel CD.
In conclusion, the present study does not support the routine use of endoscopic screening for dysplasia or SBA in patients with small bowel CD at risk of SBA. The sensitivity of the procedure was low for SBA. Small bowel strictures are the main limiting and confounding factor of screening. For clinical guidance, surgery should first be considered in CD patients with long-term small bowel disease who develop recent obstructive symptoms that suggest associated SBA.
